DavidMichaelPiontkowskyMD
Infectious Disease • Foster City, CAHIV/AIDS Medicine
Global Medical Director HIV Medical Affairs, Gilead Sciences
Dr. Piontkowsky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
333 Lakeside Drive
Foster City, CA 94404Phone+1 650-522-6162- Is this information wrong?
Education & Training
Detroit Medical Center/Wayne State UniversityFellowship, Infectious Disease, 2002 - 2004
Ross University School of MedicineClass of 1999
Certifications & Licensure
MI State Medical License 2003 - 2026
PA State Medical License 2004 - 2018
Publications & Presentations
PubMed
- 9 citationsBictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed peo...Franco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, Federico Pulido, Stephane De Wit, Linos Vandekerckhove, Juan Berenguer, Michelle L D'Antoni, Christiana Blair...> ;HIV Medicine. 2023 Jan 1
- 5 citationsSwitching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I MutationIgnacio Pérez-Valero, Josep M. Llibre, Antonella Castagna, Federico Pulido, Jean-Michel Molina, Stefan Esser, Nicolas A. Margot, Yongwu Shao, Lauren Temme, David Piont...> ;Journal of Acquired Immune Deficiency Syndromes. 2021 Apr 1
- 25 citationsBictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial.Franco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, Federico Pulido, Stéphane De Wit, Linos Vandekerckhove, Juan Berenguer, Michelle L D’Antoni, Christiana Blair...> ;Infectious Diseases and Therapy. 2021 Mar 9
- Join now to see all
Journal Articles
- SWIFT: Prospective 48 Week Study to Evaluate Efficacy and Safety of Switching to Emtricitibine/Tenofovir from Lamivudine/Abacavir in Virologically Suppressed HIV-1 Inf...Campo, R, DeJesus, E, Bredeek, UF, Henry, K, Khanlou, H, Logue, K, Brinson, C, Benson, P, Wang, HJ, White, K, Dau, L, Flaherty, J, Fralich, T, Guyer, B, Piontkowksy, D, Clinical Infectious Disesases, 6/2013
Abstracts/Posters
- Budget impact of the introduction of elvitegravir/cobicistat/emtricitabine/tenofovir, the first integrase inhibitor-based single tablet antiretroviral regimen for HIV ...Brogan, A, Talbird, SE, Thompson, JR, Kim, YA, Olson, J, Peterson, J, Piontkowsky, D, Pietrandoni, G, ISPOR, Dublin, Ireland, 11/2013
- Week 96 Renal Safety Update of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF from two phase 3 randomized controlled trialsPost, F, Winston, J, Hendry, B, Gazzard, Piontkowsky, D, Cheng, A, Rhee, M, Szwarcberg, J, Journal of International AIDS Society, 7/2013
- Elvitegravir/cobicistat/emtricitabine/tenofovir DF, demonstrates comparable efficacy to efavirenz/emtricitabine/tenofovir DF in subjects with adherence <95%Shalit, P, Cohen, C, Mills, A, Bredeek, F, Crofoot, G, Nguyen, T, Dau, T, Rhee, M, Piontkowsky, D, Szwarcberg, J, International AIDS Conference, Washington DC, 7/2013
- Join now to see all
Professional Memberships
- American Academy of HIV MedicineMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
